Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis-Reference-Cited by-同舟云学术

Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis

Published:2023-05-31 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Bhatia Neal¹^ORCID,Heim Jayme²,Schenkel Brad³,Vasquez J. Gabriel²

Affiliation:

1. Therapeutics Clinical Research, San Diego, CA, USA

2. West Michigan Dermatology, Grandville, MI, USA

3. Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA

Funder

Sun Pharma

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2023.2200872

Reference28 articles.

1. Guidelines of care for the management of psoriasis and psoriatic arthritis

2. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity

3. Quality of Life in Patients with Psoriasis: A Systematic Literature Review

4. A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions

5. Assessment of Life Quality, Stress and Physical Activity Among Patients with Psoriasis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting;Journal of Dermatological Treatment;2024-07-22

2. A New Landmark for Wellbeing in Psoriasis: The POSITIVE Study;EMJ Dermatology;2023-11-23

3. The role of inflammation in autoimmune disease: a therapeutic target;Frontiers in Immunology;2023-10-04